Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 11/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.56 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | UBE2N | P61088 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977130 | 0.92 | TNK2 (0.58) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL1787179 | 0.92 | TNK2 (0.58) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL6848486 | 0.92 | TNK2 (0.58) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL2975999 | 0.88 | KDM4E (0.74) | TNK2ALDH1A1HPGDAURKACHEK1 | |
| SCHEMBL1785983 | 0.88 | TNK2 (0.54) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL1785974 | 0.88 | KDM4E (0.74) | TNK2ALDH1A1HPGDAURKACHEK1 | |
| SCHEMBL6202574 | 0.87 | TNK2 (0.53) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL6201687 | 0.84 | ALDH1A1 (0.59) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL13354550 | 0.83 | TNK2 (0.50) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL759173 | 0.83 | EGFR (0.52) | TNK2ALDH1A1HPGDTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190212343-A1 | METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20170299599-A1 | PHOSPHORYLATION OF HISTONES AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | 2017-10-19 | — | — | US | disclosed |
| US-20170299599-A1 | PHOSPHORYLATION OF HISTONES AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | 2017-10-19 | — | — | US | disclosed |
| US-9594084-B2 | Phosphorylation of histones and uses thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2017-03-14 | — | — | US | disclosed |
| US-9594084-B2 | Phosphorylation of histones and uses thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| US-20160091498-A1 | METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2016-03-31 | — | — | US | disclosed |
| US-20160091498-A1 | METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2016-03-31 | — | — | US | disclosed |
| US-20150011567-A1 | PHOSPHORYLATION OF HISTONES AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | 2015-01-08 | — | — | US | disclosed |
| WO-2008131859-A2 | USE OF CYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1966218-A1 | NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079861-A1 | NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007079861-A1 | NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050187389-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | AMBIT BIOSCIENCES CORPORATION | 2005-08-25 | — | — | US | disclosed |
| WO-2005067546-A2 | PYRROLOPYRIMIDINE DERIVATIVES AND ANALOGS AND THEIR USE IN THE TREATMENT AND PREVENTION OF DISEASES | AMBIT BIOSCIENCES CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20050153989-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | AMBIT BIOSCIENCES CORPORATION | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170299599-A1 | PHOSPHORYLATION OF HISTONES AND USES THEREOF | H1-3, H1-4, H1-5 | TNK2 456/4885ALDH1A1 4620/4885HPGD 3989/4885 |
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | TNK2 1075/4885ALDH1A1 159/4885HPGD 1536/4885 |
| US-20050187389-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | PRKDC, PRKCA, PRKACA | TNK2 65/4885ALDH1A1 2409/4885HPGD 770/4885 |
| US-20150011567-A1 | PHOSPHORYLATION OF HISTONES AND USES THEREOF | H1-3, H1-4, H1-5 | TNK2 456/4885ALDH1A1 4620/4885HPGD 3989/4885 |
| US-20190212343-A1 | METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES | HNRNPH3, EP300, KAT2A | TNK2 413/4885ALDH1A1 4106/4885HPGD 2865/4885 |
| US-20050153989-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | PRKDC, PRKCA, PRKACA | TNK2 65/4885ALDH1A1 2409/4885HPGD 770/4885 |
| US-20160091498-A1 | METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES | HNRNPH3, EP300, KAT2A | TNK2 413/4885ALDH1A1 4106/4885HPGD 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.